Product Description
Amifostine is used protect the kidneys from harmful effects of the chemotherapy drug cisplatin in patients that receive this medication for the treatment of ovarian cancer. Amifostine is also used to decrease dryness in the mouth caused by radiation treatment after surgery for head and neck cancer. Amifostine is in a class of medications called cytoprotectants. It works by protecting against the harmful effects of chemotherapy medications and radiation treatment. (Sourced from: https://medlineplus.gov/druginfo/meds/a696014.html)
Mechanisms of Action: Cisplatin Antagonist,Free Radical Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Brazil | Canada | Chile | Colombia | Cyprus | Dominican Republic | Ecuador | France | Germany | Greece | India | Italy | Mexico | New Zealand | Pakistan | Peru | Portugal | Russia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Kingdom | United States | Venezuela
Approved Indications: Xerostomia | Hypocalcemia | Head and Neck Cancer | Ovarian Cancer | Parotid Cancer | Oncology Unspecified
Known Adverse Events: Hypotension
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Radiodermatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GRA.05.SPR.0001 | P2 |
Unknown Status |
Radiodermatitis |
2025-04-30 |